Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Arrowhead Pharma (NQ: ARWR )

26.77 +0.38 (+1.44%)
Streaming Delayed Price Updated: 1:17 PM EDT, Sep 28, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 204,234
Open 26.33
Bid (Size) 26.74 (2)
Ask (Size) 26.78 (1)
Prev. Close 26.39
Today's Range 26.04 - 26.89
52wk Range 23.09 - 42.48
Shares Outstanding 105,736,200
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Arrowhead Pharmaceuticals Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
From Arrowhead Pharmaceuticals, Inc.
Via Business Wire
Analyst Expectations for Arrowhead Pharma's Future
Via Benzinga

Performance

YTD
-30.49%
-30.49%
1 Month
-3.22%
-3.22%
3 Month
-27.49%
-27.49%
6 Month
+8.21%
+8.21%
1 Year
-14.20%
-14.20%

More News

Read More
Benzinga's Top Ratings Upgrades, Downgrades For September 19, 2023
Via Benzinga
Analyst Ratings for Arrowhead Pharma
Via Benzinga
Analyst Expectations for Arrowhead Pharma's Future
Via Benzinga
Expert Ratings for Arrowhead Pharma
Via Benzinga
Where Arrowhead Pharma Stands With Analysts
Via Benzinga
Arrowhead Presents Data on Pulmonary Pipeline at ERS 2023
From Arrowhead Pharmaceuticals, Inc.
Via Business Wire
Cramer Says 'Please Stay Away' From This EV Maker, It 'Should Not Be Public'
Via Benzinga
Arrowhead Pharmaceuticals to Participate in Upcoming September 2023 Conferences
From Arrowhead Pharmaceuticals, Inc.
Via Business Wire
Arrowhead Pharmaceuticals Reports Fiscal 2023 Third Quarter Results
From Arrowhead Pharmaceuticals, Inc.
Via Business Wire
Arrowhead Pharmaceuticals to Webcast Fiscal 2023 Third Quarter Results
From Arrowhead Pharmaceuticals Inc.
Via Business Wire
Benzinga's Top Ratings Upgrades, Downgrades For July 21, 2023
Via Benzinga
Arrowhead Pharmaceuticals Files for Regulatory Clearance to Initiate a Phase 1/2 Study of ARO-DUX4 for Facioscapulohumeral Muscular Dystrophy
From Arrowhead Pharmaceuticals, Inc.
Via Business Wire
Arrowhead Pharmaceuticals Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
From Arrowhead Pharmaceuticals, Inc.
Via Business Wire
Arrowhead Pharmaceuticals Files for Regulatory Clearance to Initiate a Phase 1 Study of ARO-SOD1
From Arrowhead Pharmaceuticals, Inc.
Via Business Wire
Arrowhead Presents Updated Data from Phase 2 SEQUOIA Study of Investigational RNAi Therapy Fazirsiran in Patients with Alpha-1 Antitrypsin Deficiency Liver Disease
From Arrowhead Pharmaceuticals, Inc.
Via Business Wire
Eli Lilly Just Lent Its Big Pharma Cachet To Verve's Nascent Gene-Editing Program For $60 Million
Via Investor's Business Daily
Arrowhead Pharmaceuticals to Participate in Upcoming June 2023 Conferences
From Arrowhead Pharmaceuticals, Inc.
Via Business Wire
The Biotech Buying Bonanza: Why The FTC's Amgen Battle Won't Chill The Spree
Via Investor's Business Daily
Arrowhead Hosts R&D Day Highlighting Its Pipeline of RNAi Therapeutics
From Arrowhead Pharmaceuticals, Inc.
Via Business Wire
Arrowhead CEO Christopher Anzalone Addresses The 'Really Important Event' In Lung Disease
Via Investor's Business Daily
What Arrowhead Pharmaceutical's Interim Data Reveals About A RNAi Therapeutic For Rare Cholesterol Disorder
Via Benzinga
Arrowhead Presents Interim Data from ARO-ANG3 Phase 2 GATEWAY Study in Patients with HoFH
From Arrowhead Pharmaceuticals Inc.
Via Business Wire
Arrowhead Pharmaceuticals Completes Enrollment of Phase 3 PALISADE Clinical Trial Evaluating ARO-APOC3 for Treatment of Familial Chylomicronemia Syndrome
From Arrowhead Pharmaceuticals Inc.
Via Business Wire
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.